GOSS Gossamer Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1728117 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-58.0%
TTM net income YoY-71.6%
TTM EPS YoY-221.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-361.9%
Net margin-344.8%
FCF margin-383.7%
EBITDA margin-361.1%
Returns
ROE-783.4%
ROA-45.2%
ROIC (approx.)—
Asset turnover0.13x
Leverage & solvency
Liabilities / assets119.1%
Debt / equity—
Current ratio4.40x
Interest coverage-13.28x
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio5.1%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $48.47M | $114.70M |
| R&D expense | $174.09M | $138.49M |
| SG&A expense | $37.63M | $36.13M |
| Operating income | -$170.73M | -$59.92M |
| Interest expense | $10.99M | $11.52M |
| Pretax income | -$170.46M | -$55.63M |
| Income tax | -$88,000 | $893,000 |
| Net income | -$170.37M | -$56.53M |
| EBITDA | -$170.70M | -$59.09M |
| EPS (basic) | -0.75 | -0.25 |
| EPS (diluted) | -0.75 | -0.25 |
| Weighted avg. shares (diluted) | 228.52M | 226.23M |
| Balance sheet | ||
| Cash & equivalents | $37.73M | $46.07M |
| Short-term investments | $99.20M | $248.44M |
| Receivables | $12.23M | $5.34M |
| Current assets | $167.64M | $309.89M |
| PP&E, net | $64,000 | $10,000 |
| Total assets | $172.25M | $315.29M |
| Current liabilities | $63.44M | $45.01M |
| Short-term debt | — | $0 |
| Long-term debt | — | $0 |
| Total debt | — | $0 |
| Total liabilities | $295.01M | $285.80M |
| Shareholders' equity | -$122.76M | $29.49M |
| Net debt | — | -$46.07M |
| Shares outstanding | 2.92M | 226.60M |
| Cash flow statement | ||
| Operating cash flow | -$171.27M | -$3.47M |
| Capital expenditure | $79,000 | $0 |
| Free cash flow | -$171.34M | -$3.47M |
| Investing cash flow | $156.36M | $29.02M |
| Financing cash flow | $6.42M | -$11.49M |
| Depreciation & amortization | $24,000 | $833,000 |
| Stock-based compensation | $10.55M | $20.62M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.